|
| Category | Funding IC | Project Number | Sub Project # | Project Title | PI Name | Org Name | State / Country | Amount |
|
Lymphoma
|
NIAID
|
1K22AI070317-01A1
|
|
Essential role of transcription factor Foxp1 in B cell development and function
|
HU, HUI
|
WISTAR INSTITUTE
|
PA
|
$162,000
|
|
Lymphoma
|
NCI
|
4R37CA054281-16
|
|
Multiethnic Cohort Study of Diet and Cancer
|
KOLONEL, LAURENCE
|
UNIVERSITY OF HAWAII AT MANOA
|
HI
|
$2,292,128
|
|
Lymphoma
|
NCI
|
4R37CA042245-23
|
|
Regulation of replication and latency EBV EBNAs
|
HAYWARD, S
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$367,373
|
|
Lymphoma
|
NCI
|
5F31CA126523-02
|
|
Contributions of Epstein-Barr Virus EBNA2 and EBNA-LP to B cell immortalization
|
ECHENDU, CHISAROKA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$35,140
|
|
Lymphoma
|
NIAID
|
5R01AI058057-05
|
|
Function of the gammaHV68 M2 Antigen
|
SPECK, SAMUEL
|
EMORY UNIVERSITY
|
GA
|
$353,697
|
|
Lymphoma
|
NIEHS
|
5F32ES014777-02
|
|
Role of estrogen receptor beta in cancer prevention by dietary indole-3-carbinol
|
BENNINGHOFF, ABBY
|
OREGON STATE UNIVERSITY
|
OR
|
$24,398
|
|
Lymphoma
|
NIAID
|
5R01AI057947-05
|
|
IKK Signals in Lymphocyte Physiology and Pathology
|
RAJEWSKY, KLAUS
|
IMMUNE DISEASE INSTITUTE, INC.
|
MA
|
$439,502
|
|
Lymphoma
|
NIGMS
|
5R37GM032741-26
|
|
INTRACHROMOSOMAL RECOMBINATION IN MAMMALIAN CELLS
|
LISKAY, R
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$354,186
|
|
Lymphoma
|
NCI
|
5R01CA100925-04
|
|
Role of P80 pro-IL-16 in T Cell Malignancy
|
ZHANG, YUJUN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$282,526
|
|
Lymphoma
|
NCI
|
5R01CA116093-02
|
|
Effects of human SWI/SNF-associated PRMT5 on lymphomagenesis
|
SIF, SAID
|
OHIO STATE UNIVERSITY
|
OH
|
$256,500
|
|
Lymphoma
|
NCI
|
5R01CA124621-02
|
|
Role of Arsenic Trioxide in Primary Effusion Lymphoma
|
CHAUDHARY, PREET
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$278,353
|
|
Lymphoma
|
NIAID
|
1R13AI075650-01
|
|
Keystone Symposium on Lymphocyte Activation and Signaling
|
ROBERTSON, ANDREW
|
KEYSTONE SYMPOSIA
|
CO
|
$10,000
|
|
Lymphoma
|
NCI
|
5R01CA100266-03
|
|
Tumor Suppressors in Lymphocytes
|
WABL, MATTHIAS
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$265,854
|
|
Lymphoma
|
NCI
|
5R01CA106662-04
|
|
Dendritic Cell Threapy for Cutaneous T-Cell Lymphoma
|
FALO, LOUIS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$288,651
|
|
Lymphoma
|
NCI
|
5R01CA036327-25
|
|
N-Ras Signaling in Tumorigenesis and Physiology
|
PELLICER, ANGEL
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$458,935
|
|
Lymphoma
|
NIAID
|
5R01AI063058-04
|
|
Roles of the Artemis nuclease in DNA repair and disease
|
SEKIGUCHI, JOANN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$279,700
|
|
Lymphoma
|
NIAID
|
5R01AI063345-03
|
|
Trophic Regulation in T Cell Homeostasis and Disease
|
RATHMELL, JEFFREY
|
DUKE UNIVERSITY
|
NC
|
$371,495
|
|
Lymphoma
|
NIDCR
|
5R01DE016669-04
|
|
EBV Entry and Spread in the Oral Cavity
|
HUTT-FLETCHER, LINDSEY
|
LOUISIANA STATE UNIV HSC SHREVEPORT
|
LA
|
$339,934
|
|
Lymphoma
|
NIAID
|
5R01AI061017-04
|
|
Epstein-Barr virus glycoproteins and virus spread
|
HUTT-FLETCHER, LINDSEY
|
LOUISIANA STATE UNIV HSC SHREVEPORT
|
LA
|
$303,468
|
|
Lymphoma
|
NCI
|
5R01CA078384-10
|
|
E2A AS A POTENTIAL TUMOR SUPPRESSOR
|
MURRE, CORNELIS
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$384,245
|
|
Lymphoma
|
NCI
|
5R01CA107469-04
|
|
Role of EZH2 in Breast Cancer
|
KLEER, CELINA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$257,343
|
|
Lymphoma
|
NCI
|
5R01CA104348-05
|
|
Transcriptional silencing by the Bcl-6 oncoprotein
|
MELNICK, ARI
|
YESHIVA UNIVERSITY
|
NY
|
$259,688
|
|
Lymphoma
|
NCI
|
5U01CA062406-14
|
|
NABTT-New Approaches to Brain Tumor Therapy (CNSC)
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$57,838
|
|
Lymphoma
|
NCI
|
5R01CA084069-09
|
|
Mechanisms of Cell Cycle Associated Neoplasia
|
CLURMAN, BRUCE
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$348,574
|
|
Lymphoma
|
NCI
|
5R01CA080320-10
|
|
MYC Dependent Pathways in Apoptosis and Lymphomagenesis
|
COLE, MICHAEL
|
DARTMOUTH COLLEGE
|
NH
|
$341,132
|
|
Lymphoma
|
NCI
|
5R01CA058554-14
|
|
Molecular genetics of Mouse Lung Tumors
|
YOU, MING
|
WASHINGTON UNIVERSITY
|
MO
|
$248,200
|
|
Lymphoma
|
NCI
|
5R01CA072649-11
|
|
Somatic Mutation of Ig Variable Regions
|
SCHARFF, MATTHEW
|
YESHIVA UNIVERSITY
|
NY
|
$397,545
|
|
Lymphoma
|
NCI
|
5R01CA058853-15
|
|
Regulation of EBV Infection in Epithelial Cells
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$278,599
|
|
Lymphoma
|
NCI
|
1R01CA130826-01
|
|
Software & Hardware Inference Engines for Automated Determination of Primary Cell
|
NOLAN, GARRY
|
STANFORD UNIVERSITY
|
CA
|
$1,671,372
|
|
Lymphoma
|
NCI
|
5F32CA123777-03
|
|
Understanding the Role of Autophagy in Cancer
|
DORSEY, FRANK
|
SCRIPPS RESEARCH INSTITUTE
|
CA
|
$51,278
|
|
Lymphoma
|
NCI
|
5R01CA095431-04
|
|
Regulation of the Tp12 Kinase
|
TSICHLIS, PHILIP
|
TUFTS MEDICAL CENTER
|
MA
|
$274,719
|
|
Lymphoma
|
NCI
|
5R01CA125658-02
|
|
Rac GTPases as Targets in Lymphomagenesis
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
OH
|
$285,000
|
|
Lymphoma
|
NCI
|
5R01CA030356-27
|
|
EBV Genome Expression:Localization of Specific Functions
|
HAYWARD, S
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$330,440
|
|
Lymphoma
|
NCI
|
5R01CA113872-04
|
|
Role of OCA-B in B cell differentiation and malignancy
|
ROEDER, ROBERT
|
ROCKEFELLER UNIVERSITY
|
NY
|
$522,190
|
|
Lymphoma
|
NIAID
|
1R21AI076720-01
|
|
Wnt/b-catenin signaling in T-cell transformation
|
GOUNARI, FOTINI
|
UNIVERSITY OF CHICAGO
|
IL
|
$191,875
|
|
Lymphoma
|
NCI
|
5R01CA100875-05
|
|
Mechanisms of T Cell Tumorigenesis
|
CHEN, JIANZHU
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$238,942
|
|
Lymphoma
|
NCI
|
5R01CA091791-07
|
|
Reactivation of Kaposi's sarcoma-associated herpesvirus
|
SUN, REN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$281,463
|
|
Lymphoma
|
NHLBI
|
1K08HL091517-01
|
|
Annexin 2 in Lymphoproliferative Angiogenesis
|
RUAN, JIA
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$131,490
|
|
Lymphoma
|
NCI
|
5R01CA100555-04
|
|
Lymphoma Defined Cytogenetically for Epidemiologic Study
|
CHIU, BRIAN
|
NORTHWESTERN UNIVERSITY
|
IL
|
$202,456
|
|
Lymphoma
|
NCI
|
5R01CA121180-03
|
|
A Comprehensive Investigation of Viral-induced Lymphomagenesis
|
FISHER, SUSAN
|
UNIVERSITY OF ROCHESTER
|
NY
|
$267,494
|
|
Lymphoma
|
NIAID
|
1R21AI076747-01
|
|
Exploring the Mechanisms of 53BP1-driven Immune Deficiency and DNA Repair
|
CARPENTER, PHILLIP
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
TX
|
$223,685
|
|
Lymphoma
|
NCI
|
5R01CA065883-14
|
|
Epstein Barr Virus Latency
|
THORLEY-LAWSON, DAVID
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$304,330
|
|
Lymphoma
|
NCI
|
1K99CA131474-01
|
|
Post-Transcriptional Regulation of Polycistronic MicroRNAs in Mammalian Cells
|
NEILSON, JOEL
|
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
|
MA
|
$94,499
|
|
Lymphoma
|
NCI
|
5R01CA104588-05
|
|
RAG-induced DNA damage: mechanisms and responses
|
ROTH, DAVID
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
NY
|
$290,532
|
|
Lymphoma
|
NCI
|
5R01CA109518-04
|
|
Cellular Targets for Gallium Compounds in Lymphoma
|
CHITAMBAR, CHRISTOPHER
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$255,337
|
|
Lymphoma
|
NCI
|
5R01CA105043-05
|
|
Pathogenesis & Therapy of 8p11 Leukemia/Lymphoma
|
VAN ETTEN, RICHARD
|
TUFTS MEDICAL CENTER
|
MA
|
$316,836
|
|
Lymphoma
|
NCI
|
5R01CA100053-04
|
|
Cell Autonomy and Tumor Suppression by CDK inhibitors
|
FERO, MATTHEW
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$340,846
|
|
Lymphoma
|
NCI
|
5U10CA013612-35
|
|
SOUTHWEST ONCOLOGY GROUP
|
MILLER, THOMAS
|
UNIVERSITY OF ARIZONA
|
AZ
|
$266,506
|
|
Lymphoma
|
NHLBI
|
1R15HL091511-01
|
|
Gfi-1 in the regulation of p21Cip
|
DONG, FAN
|
UNIVERSITY OF TOLEDO
|
OH
|
$216,000
|
|
Lymphoma
|
NCI
|
2R01CA092104-05A2
|
|
Biologic Therapy for B-cell non-Hodgkin's Lymphoma
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$258,741
|
|
Lymphoma
|
NCI
|
5R01CA109474-03
|
|
Doxorubicin-Immunoconjugate Therapy of Non-Hodgkin's Lymphoma
|
STEIN, RHONA
|
CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY
|
NJ
|
$255,220
|
|
Lymphoma
|
NIAID
|
5R01AI064345-04
|
|
Role of RNA silencing in B cell development and function
|
RAJEWSKY, KLAUS
|
IMMUNE DISEASE INSTITUTE, INC.
|
MA
|
$567,883
|
|
Lymphoma
|
NCI
|
5R01CA107300-05
|
|
A NOVEL MECHANISM OF TCL1 TUMORIGENESIS
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$270,281
|
|
Lymphoma
|
NCI
|
7R01CA102142-05
|
|
Role of POZ-zinc finger proteins in hemopoietic malignacies
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$330,443
|
|
Lymphoma
|
NIGMS
|
5R01GM048026-16
|
|
V(D)J Recombination Activating Genes-Functional Analysis
|
OETTINGER, MARJORIE
|
MASSACHUSETTS GENERAL HOSPITAL
|
MA
|
$399,324
|
|
Lymphoma
|
NCI
|
5R01CA117827-04
|
|
Function of the Epstein-Barr Virus EBNA-A3 Protein
|
SAMPLE, CLARE
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$251,251
|
|
Lymphoma
|
NCI
|
1R01CA122569-01A2
|
|
Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma
|
ROOK, ALAIN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$283,500
|
|
Lymphoma
|
NIAID
|
1R01AI068907-01A2
|
|
Transcriptional Control of Th-POK, a Key Regulator of Lineage Control
|
KAPPES, DIETMAR
|
INSTITUTE FOR CANCER RESEARCH
|
PA
|
$472,923
|
|
Lymphoma
|
NCI
|
2R01CA076287-10
|
|
Pretargeted Radioimmunotherapy of CD20+ Lymphomas
|
PRESS, OLIVER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$380,807
|
|
Lymphoma
|
NCI
|
5R01CA108951-04
|
|
Oncogenic properties of interferon regulatory factor 7
|
ZHANG, LUWEN
|
UNIVERSITY OF NEBRASKA LINCOLN
|
NE
|
$217,299
|
|
Lymphoma
|
NCI
|
5R01CA119066-03
|
|
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2
|
LOOK, A
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$303,525
|
|
Lymphoma
|
NIAID
|
5R01AI060729-03
|
|
Stage-specific Signaling in Peripheral B Cell Selection
|
KHAN, WASIF
|
VANDERBILT UNIVERSITY
|
TN
|
$365,542
|
|
Lymphoma
|
NCI
|
1R01CA124540-01A1
|
|
Multiple Roles of the API2 Moiety in API2-MALT1-Mediated Lymphomagenesis
|
MCALLISTER-LUCAS, LINDA
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$319,230
|
|
Lymphoma
|
NCI
|
5R01CA056645-16
|
|
FUNCTION OF EBV EBNA-3C IN B CELL IMMORTALIZATION
|
SAMPLE, CLARE
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
PA
|
$230,935
|
|
Lymphoma
|
NCI
|
5R01CA077553-09
|
|
Mechanism of T cell lymphoma in E protein deficiency
|
SUN, XIAO-HONG
|
OKLAHOMA MEDICAL RESEARCH FOUNDATION
|
OK
|
$285,911
|
|
Lymphoma
|
NIAID
|
2R01AI018757-26
|
|
Host Immunity to EBV Infection in Vitro and in VIvo
|
THORLEY-LAWSON, DAVID
|
TUFTS UNIVERSITY BOSTON
|
MA
|
$410,729
|
|
Lymphoma
|
NCI
|
1R01CA122539-01A2
|
|
Lymphoproliferative Disorders in Primary Immunodeficiencies
|
ROUTES, JOHN
|
MEDICAL COLLEGE OF WISCONSIN
|
WI
|
$314,363
|
|
Lymphoma
|
NCI
|
1R01CA122645-01A1
|
|
Rituximab Elicitation of Tumor Specific T-cell Responses in Lymphoma Patients
|
BERNSTEIN, STEVEN
|
UNIVERSITY OF ROCHESTER
|
NY
|
$329,408
|
|
Lymphoma
|
NCI
|
2R01CA031534-24
|
|
MAR Mediated Control of The IgH Enhancer
|
TUCKER, PHILIP
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$257,359
|
|
Lymphoma
|
NCI
|
5R21CA126463-02
|
|
EBV Pathogenesis in a New Mouse Model
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$146,735
|
|
Lymphoma
|
NCI
|
5R01CA124332-02
|
|
Regulation of KSHV infection and replication by MAPK pathways
|
GAO, SHOU-JIANG
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$277,400
|
|
Lymphoma
|
NCI
|
5R21CA121569-02
|
|
BLys inhibition using TACI-Fc in patients with B-bell non-Hodgkins' Lymphoma
|
ANSELL, STEPHEN
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$281,200
|
|
Lymphoma
|
NCI
|
5U10CA046282-21
|
|
Southwest Oncology Group
|
STIFF, PATRICK
|
LOYOLA UNIVERSITY CHICAGO
|
IL
|
$382,959
|
|
Lymphoma
|
NCI
|
2P01CA100730-06
|
0006
|
Role of Bone Microenvironment in Tax Induced Malignancies
|
WEILBAECHER, KATHERINE
|
WASHINGTON UNIVERSITY
|
MO
|
$260,361
|
|
Lymphoma
|
NCI
|
2P01CA100730-06
|
0005
|
Role of Inflammation in Tax-mediated Tumorigenesis
|
RATNER, LEE
|
WASHINGTON UNIVERSITY
|
MO
|
$298,986
|
|
Lymphoma
|
NCI
|
4R37CA012055-36
|
|
Studies of Epstein-Barr Virus
|
MILLER, I.
|
YALE UNIVERSITY
|
CT
|
$451,285
|
|
Lymphoma
|
NCI
|
5R01CA090233-07
|
|
Lineage Commitment Mechanisms in Lymphoid Precursors
|
ROTHENBERG, ELLEN
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
CA
|
$363,528
|
|
Lymphoma
|
NCI
|
5R01CA120185-02
|
|
c-Myc-regulated microRNAs in normal and pathologic cellular physiology
|
MENDELL, JOSHUA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$309,168
|
|
Lymphoma
|
NCI
|
2R01CA083937-06A2
|
|
Functional analysis of Bfl-1/A1 in apoptosis and oncogenesis
|
GELINAS, CELINE
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
NJ
|
$247,822
|
|
Lymphoma
|
NIDDK
|
5R01DK047636-13
|
|
Hematopoietic specific Genes in Stem Cell Development
|
LIM, BING
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$334,101
|
|
Lymphoma
|
NIAID
|
1R21AI073627-01A1
|
|
Novel Carrier for Polysaccharide Conjugates and an EBV Vaccine
|
SNAPPER, CLIFFORD
|
HENRY M. JACKSON FDN FOR THE ADV MIL/MED
|
MD
|
$192,375
|
|
Lymphoma
|
NCI
|
5R01CA085573-08
|
|
Role of the BCL 6 Proto Oncogene in B Cell Lymphomas
|
YE, BIHUI
|
YESHIVA UNIVERSITY
|
NY
|
$347,533
|
|
Lymphoma
|
NCI
|
5R01CA070723-12
|
|
Genetic Analysis of EBV's Immortalizing Genes
|
SUGDEN, WILLIAM
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$293,829
|
|
Lymphoma
|
NCI
|
5R01CA103646-05
|
|
KSHV vFLIP in B cell survival
|
CESARMAN, ETHEL
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$326,554
|
|
Lymphoma
|
NCI
|
5R01CA103642-05
|
|
Immune surveillance in murine gammaherpesvirus infection
|
USHERWOOD, EDWARD
|
DARTMOUTH COLLEGE
|
NH
|
$279,728
|
|
Lymphoma
|
NCI
|
5R01CA033192-21
|
|
Transformation by Reticuloendotheliosis Virus
|
BOSE, HENRY
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$302,573
|
|
Lymphoma
|
NCRR
|
1S10RR024749-01
|
|
Console for a 4.7 T small animal MRI system
|
PICKUP, STEPHEN
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$499,858
|
|
Lymphoma
|
NIAMS
|
5K23AR051125-05
|
|
Investigating the Risk of Lymphoma in Psoriasis Patients
|
GELFAND, JOEL
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$132,462
|
|
Lymphoma
|
NCI
|
5R01CA093237-07
|
|
Nuclear Accumulation of Cyclin D1 and Oncogenesis
|
DIEHL, J
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$294,539
|
|
Lymphoma
|
NCI
|
5R21CA126060-02
|
|
CD 74 Directed Immunotherapy for B Cell Malignancies
|
LEONARD, JOHN
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$327,262
|
|
Lymphoma
|
NCI
|
1R43CA132390-01
|
|
Therapeutic Cancer Vaccine for Non-Hodgkin's Lymphoma
|
ROBB, RICHARD
|
XEME BIOPHARMA, INC
|
NJ
|
$167,401
|
|
Lymphoma
|
NCI
|
5R01CA117935-02
|
|
p53-Independent Pathways in Mdm2-Mediated Transformation
|
EISCHEN, CHRISTINE
|
VANDERBILT UNIVERSITY
|
TN
|
$291,850
|
|
Lymphoma
|
NCI
|
5R01CA106550-04
|
|
The Tumor Suppression Potential of NF-kappaB2 p100
|
DING, HAN-FEI
|
UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS
|
OH
|
$1,949
|
|
Lymphoma
|
NCI
|
5K23CA123149-02
|
|
Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy
|
NEELAPU, SATTVA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$136,080
|
|
Lymphoma
|
NCI
|
5U10CA073590-12
|
|
SWOG Institutional Grant
|
SONDAK, VERNON
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$1
|
|
Lymphoma
|
NINR
|
1R43NR010441-01A1
|
|
Telenursing Model for Management of Chemotherapy Side Effects
|
YANG, DERSHUNG
|
CARACAL, INC.
|
IL
|
$99,767
|
|
Lymphoma
|
NCI
|
7R01CA106156-05
|
|
Cell growth deregulation by KSHV protein
|
JUNG, JAE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$285,151
|
|
Lymphoma
|
NCI
|
1F32CA132307-01
|
|
Phosphorylation sites that regulate c-Myc's proliferative and apoptotic functions
|
BYERS, SARAH
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$49,646
|
|
Lymphoma
|
NCI
|
1F32CA132350-01
|
|
Coordinate Suppression of B Cell Lymphoma by PTEN and SHIP
|
MILETIC SEDY, ANA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$49,646
|
|
Lymphoma
|
NCI
|
5R01CA114504-04
|
|
PRDI-BF1 and histone methyltransferase in lymphoma
|
WRIGHT, KENNETH
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$230,795
|
|
Lymphoma
|
NCI
|
5R01CA068328-12
|
|
c-Myc Expression during Lymphomagenesis
|
RUDDELL, M
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$337,199
|
|
Lymphoma
|
NCI
|
2P01CA094237-06
|
0001
|
OVERCOMING TUMOR EVASION MECHANISMS IN HODGKIN DISEASE
|
ROONEY, CLIONA
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$268,054
|
|
Lymphoma
|
NCI
|
2P01CA094237-06
|
0002
|
THE ROLE AND MECHANISMS OF CD4+ T CELLS IN ANTITUMOR IMMUNITY
|
WANG, RONGFU
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$268,054
|
|
Lymphoma
|
NCI
|
5R01CA075922-12
|
|
Rhesus HHV-8 homologue in AIDS-related malignancies
|
WONG, SCOTT
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$595,989
|
|
Lymphoma
|
NCI
|
5R01CA111807-04
|
|
The Role of Toll-Like Receptors in Cancer Immunotherapy
|
YANG, YIPING
|
DUKE UNIVERSITY
|
NC
|
$288,390
|
|
Lymphoma
|
NCI
|
5R01CA116933-02
|
|
Preventing Tumorigenesis in Developing Lymphocytes
|
ZHU, CHENGMING
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$292,600
|
|
Lymphoma
|
NCI
|
1P50CA121973-01A1
|
0005
|
Augmentation of Dendritic Cell-based Immunotherapy for Sezary Syndrome by T-reg D
|
FALO, LOUIS
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$124,792
|
|
Lymphoma
|
NCI
|
5R01CA118559-02
|
|
IN VIVO 31P MRS STUDIES OF NON-HODGKIN'S LYMPHOMA
|
BROWN, TRUMAN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$1,174,250
|
|
Lymphoma
|
NIDDK
|
5K01DK074555-03
|
|
Genetic Modifiers of the Anti-apoptotic Functions of Bcl-2
|
JETTE, CICELY
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$134,110
|
|
Lymphoma
|
NCI
|
5R01CA105157-05
|
|
Pathways of Death and Survival in EBV B Cell Lymphomas
|
MARTINEZ, OLIVIA
|
STANFORD UNIVERSITY
|
CA
|
$248,803
|
|
Lymphoma
|
NCI
|
5K22CA113493-02
|
|
Role of MAP kinases in anaplastic large cell lymphoma
|
ZU, YOULI
|
METHODIST HOSPITAL RESEARCH INSTITUTE
|
TX
|
$151,200
|
|
Lymphoma
|
NCI
|
7R01CA104596-04
|
|
Expression and Function of Tob in T Lymphocytes
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
MA
|
$318,352
|
|
Lymphoma
|
NCI
|
5R03CA125831-02
|
|
Occupational risk factors for NHL and NHL subtypes: an InterLymph-based analysis
|
MANNETJE, ANDREA
|
MASSEY UNIVERSITY
|
NEW ZE
|
$55,123
|
|
Lymphoma
|
NCI
|
5R01CA113794-04
|
|
The function of Snf5, an epigenetic tumor suppressor
|
ROBERTS, CHARLES
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$320,225
|
|
Lymphoma
|
NCI
|
5R01CA124311-02
|
|
Regulation of Epstein Barr virus reactivation through the co-activators, CBP/p300
|
FLEMINGTON, ERIK
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$254,790
|
|
Lymphoma
|
NCI
|
5R01CA085888-09
|
|
Malignant Complications of Chronic HCV
|
LOFFREDO, CHRISTOPHER
|
GEORGETOWN UNIVERSITY
|
DC
|
$297,351
|
|
Lymphoma
|
NCI
|
5R21CA119918-02
|
|
Antiangiogenic Therapy for AIDS-Associated Lymphomas
|
ROCHFORD, ROSEMARY
|
UPSTATE MEDICAL UNIVERSITY
|
NY
|
$157,000
|
|
Lymphoma
|
NCI
|
5R01CA058524-14
|
|
Regulation of EBV Transcription in Burkitt's Lymphoma
|
SPECK, SAMUEL
|
EMORY UNIVERSITY
|
GA
|
$272,412
|
|
Lymphoma
|
NCI
|
5R01CA114416-03
|
|
Epstein-Barr Virus-Enhanced Tumor Progression
|
SIXBEY, JOHN
|
LOUISIANA STATE UNIV HSC SHREVEPORT
|
LA
|
$283,896
|
|
Lymphoma
|
NCI
|
5R01CA081133-10
|
|
Post-transcriptional Gene Regulation by EBV SM Protein
|
SWAMINATHAN, SANKAR
|
UNIVERSITY OF FLORIDA
|
FL
|
$248,329
|
|
Lymphoma
|
NCI
|
5R01CA113518-03
|
|
Tetravalent antibodies with altered FcRn binding sites
|
SMALLSHAW, JOAN
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
TX
|
$173,790
|
|
Lymphoma
|
NIA
|
5R01AG026661-03
|
|
Role of RecQ Helicases to Prevent Senescence By c-Myc
|
GRANDORI, CARLA
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$303,731
|
|
Lymphoma
|
NCI
|
5R01CA089305-07
|
|
MYC's Role in the Initiation and Maintenance of Cancer
|
FELSHER, DEAN
|
STANFORD UNIVERSITY
|
CA
|
$379,965
|
|
Lymphoma
|
NCI
|
5R01CA102667-04
|
|
Effects of Malaria on EBV Persistence in Children
|
ROCHFORD, ROSEMARY
|
UPSTATE MEDICAL UNIVERSITY
|
NY
|
$261,947
|
|
Lymphoma
|
NCI
|
7R01CA109697-04
|
|
Herpesvirus saimiri TIP
|
JUNG, JAE
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
CA
|
$274,719
|
|
Lymphoma
|
NCI
|
5R01CA117802-03
|
|
MYC-induced breach of B-cell anergy in AIDS-related NHLs
|
REFAELI, YOSEF
|
NATIONAL JEWISH HEALTH
|
CO
|
$241,983
|
|
Lymphoma
|
NCI
|
5R01CA092229-08
|
|
Helicobacter Host Interactions in Animal Models
|
FALKOW, STANLEY
|
STANFORD UNIVERSITY
|
CA
|
$283,219
|
|
Lymphoma
|
NCI
|
5R01CA104818-05
|
|
SV40 Pathogenesis of Human Infections
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$467,229
|
|
Lymphoma
|
NCI
|
5R01CA071768-12
|
|
Redox Control of Apoptosis Signaling
|
BRIEHL, MARGARET
|
UNIVERSITY OF ARIZONA
|
AZ
|
$221,264
|
|
Lymphoma
|
NCI
|
5R01CA107489-05
|
|
Role of BCL6 Mutation in Lymphomagenesis
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$317,808
|
|
Lymphoma
|
NCI
|
5R01CA101795-05
|
|
Novel Strategies for Immunotherapy of Cancer
|
WANG, RONGFU
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$263,284
|
|
Lymphoma
|
NCI
|
5R03CA128052-02
|
|
Lymphoma in Autoimmune Disease: Consequence of Immune Suppression or Stimulation?
|
BERNATSKY, SASHA
|
MCGILL UNIVERSITY HEALTH CTR RES INST
|
CANADA
|
$54,000
|
|
Lymphoma
|
NCI
|
5K23CA113775-03
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$134,015
|
|
Lymphoma
|
NCI
|
5R01CA106705-04
|
|
Cyclic AMP-mediated apoptosis in lymphoid malignancies
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
MA
|
$241,199
|
|
Lymphoma
|
NHLBI
|
5R21HL085189-02
|
|
Role of vFLIP K13 in Bone Marrow Failure Syndrome Associated with Infection by Hu
|
CHAUDHARY, PREET
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$222,750
|
|
Lymphoma
|
NCI
|
5R01CA109232-05
|
|
Regulation of the KSHV latent promoter
|
DITTMER, DIRK
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$225,602
|
|
Lymphoma
|
NCI
|
5R01CA071796-11
|
|
Multistep Lymphomagenesis/Tumorigenesis in Transgenic Mice: Protein Kinase Ck2
|
SELDIN, DAVID
|
BOSTON MEDICAL CENTER
|
MA
|
$275,767
|
|
Lymphoma
|
NIDCR
|
5R01DE018304-02
|
|
ART Modulation of Viral Pathogenesis in Oral Epithelia
|
DITTMER, DIRK
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$317,667
|
|
Lymphoma
|
NCI
|
5R01CA047763-21
|
|
Transformation of Cells by the REL Oncogene
|
GILMORE, THOMAS
|
BOSTON UNIVERSITY
|
MA
|
$275,637
|
|
Lymphoma
|
NCI
|
5R01CA102646-04
|
|
USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
|
GRUPP, STEPHAN
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$311,617
|
|
Lymphoma
|
NCI
|
5R21CA126119-02
|
|
Regulation of the P13K/AKT pathway in Waldenstrom Macroglobulinemia
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$321,536
|
|
Lymphoma
|
NIGMS
|
5F32GM076816-02
|
|
Organocatalytic Asymmetric Cascade Reactions
|
NICEWICZ, DAVID
|
PRINCETON UNIVERSITY
|
NJ
|
$46,826
|
|
Lymphoma
|
NCI
|
5U10CA016116-35
|
|
Eastern Cooperative Oncology Group
|
FORASTIERE, ARLENE
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$279,595
|
|
Lymphoma
|
NCI
|
5R01CA068051-13
|
|
Pathogenesis of Epstein-Barr Virus Infection
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$407,881
|
|
Lymphoma
|
NCI
|
5K08CA105064-05
|
|
A Pull-Push Strategy for Lymphoma Immunotherapy
|
SONG, WENRU
|
BAYLOR RESEARCH INSTITUTE
|
TX
|
$128,547
|
|
Lymphoma
|
NCI
|
5U10CA021076-33
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP - WISCONSIN STUDIES
|
KAHL, BRAD
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$610,603
|
|
Lymphoma
|
NCI
|
5R01CA095043-05
|
|
Activation of the LMP-1 Protein of Epstein-Barr Virus
|
MARTIN, JENNIFER
|
UNIVERSITY OF COLORADO AT BOULDER
|
CO
|
$231,698
|
|
Lymphoma
|
NCI
|
5R01CA085177-09
|
|
Role of orf-K13, an HHV8 Encoded vFLIP, in the Pathogenesis of AIDS-related Malig
|
CHAUDHARY, PREET
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
PA
|
$236,554
|
|
Lymphoma
|
NIAID
|
5R01AI076972-02
|
|
Programming of CD8+ T Cell Tolerance by B Cell APC
|
SCHOENBERGER, STEPHEN
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
CA
|
$460,020
|
|
Lymphoma
|
NCI
|
5R01CA105001-05
|
|
MS4A Family Members in Health and Disease
|
TEDDER, THOMAS
|
DUKE UNIVERSITY
|
NC
|
$239,473
|
|
Lymphoma
|
NCI
|
5R01CA063417-10
|
|
Proliferative Effects of HTLV-1
|
RATNER, LEE
|
WASHINGTON UNIVERSITY
|
MO
|
$317,369
|
|
Lymphoma
|
FIC
|
1R03TW007821-01A1
|
|
Micronutrient Malnutrition and EBV Persistence in Children
|
ROCHFORD, ROSEMARY
|
UPSTATE MEDICAL UNIVERSITY
|
NY
|
$39,031
|
|
Lymphoma
|
NIAID
|
5R13AI066870-04
|
|
Lymphocytes and the Immune System Molecular, Cellular and Interactive Mechanisms
|
ROTHENBERG, ELLEN
|
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
|
MD
|
$1
|
|
Lymphoma
|
NCI
|
5R01CA127238-02
|
|
Herpesvirus-induced telomerase dysregulation and tumor formation
|
OSTERRIEDER, NIKOLAUS
|
CORNELL UNIVERSITY ITHACA
|
NY
|
$228,723
|
|
Lymphoma
|
NCI
|
5R01CA106159-04
|
|
Role of Epstein-Barr virus LMP1 in lymphoma
|
IZUMI, KENNETH
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
TX
|
$218,727
|
|
Lymphoma
|
NCI
|
5R01CA113579-04
|
|
Role and therapeutical potential of Cdk4/6 in B-lymphoma
|
ZOU, XIANGHONG
|
OHIO STATE UNIVERSITY
|
OH
|
$193,715
|
|
Lymphoma
|
NCI
|
5R03CA128006-02
|
|
Proteomic biomarkers for lymphoma
|
DENIS, GERALD
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
MA
|
$81,250
|
|
Lymphoma
|
NCI
|
5K01CA106596-05
|
|
BAD Intergrates Glycolysis and Apoptosis
|
DANIAL, NIKA
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$158,490
|
|
Lymphoma
|
NICHD
|
5R01HD037091-11
|
|
Regulation of B Cell Development and Signaling by Btk
|
RAWLINGS, DAVID
|
CHILDREN'S HOSPITAL AND REG MEDICAL CTR
|
WA
|
$324,065
|
|
Lymphoma
|
NCI
|
1R01CA133046-01
|
|
Novel Mechanisms by which RAD18 and POLZ affect Response to Anticancer Agents
|
CANMAN, CHRISTINE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$283,860
|
|
Lymphoma
|
NCI
|
5R01CA068682-18
|
|
Biomedical Applications of Expanded Porphyrins
|
SESSLER, JONATHAN
|
UNIVERSITY OF TEXAS AUSTIN
|
TX
|
$305,354
|
|
Lymphoma
|
NIBIB
|
5R21EB006483-02
|
|
Analysis of Kaposi's sarcoma-associated herpesvirus infection using Raman tweezer
|
AKULA, SHAW
|
EAST CAROLINA UNIVERSITY
|
NC
|
$139,650
|
|
Lymphoma
|
NCI
|
1R01CA133027-01
|
|
EBV's Plasmid Replicon: Its Synthesis, Partitioning, and Maintenance of Tumors
|
SUGDEN, WILLIAM
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$300,378
|
|
Lymphoma
|
NCI
|
5R01CA111185-05
|
|
K-bZIP and Transcriptional Regulation of KSHV
|
KUNG, HSING-JIEN
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$223,860
|
|
Lymphoma
|
NCI
|
5T32CA009140-34
|
|
Immunobiology of normal and neoplastic lymphocytes
|
PATERSON, YVONNE
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$647,893
|
|
Lymphoma
|
NIDDK
|
1K01DK080894-01
|
|
DNA EXCHANGE DURING STOMACH COLONIZATION BY HELICOBACTER PYLORI
|
DORER, MARION
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$98,264
|
|
Lymphoma
|
NIAID
|
5K08AI062732-04
|
|
Early cellular immune responses to EBV
|
BHADURI-MCINTOSH, SUMITA
|
YALE UNIVERSITY
|
CT
|
$136,620
|
|
Lymphoma
|
NCI
|
5R01CA093729-07
|
|
Repair of Genome Destabilizing DNA Structures
|
VASQUEZ, KAREN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$307,161
|
|
Lymphoma
|
NCI
|
5K22CA120147-02
|
|
Interaction of TCL1 with a novel exoribonuclease
|
FRENCH, SAMUEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$152,820
|
|
Lymphoma
|
NCI
|
5R01CA121039-02
|
|
B Cell Lymphoma Therapy
|
CHOI, YONG
|
OCHSNER CLINIC FOUNDATION
|
LA
|
$244,245
|
|
Lymphoma
|
NCI
|
5R01CA040041-23
|
|
SURFACE ANTIGENS OF MURINE T LYMPHOMAS
|
ALLISON, JAMES
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$311,649
|
|
Lymphoma
|
NCI
|
5R01CA042755-22
|
|
Mechanism of Steroid Action in Lymphoid Malignancy
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$311,299
|
|
Lymphoma
|
NCI
|
5R01CA113874-04
|
|
Immunotherapy with Gamma Delta T Cells for B Cell Tumors
|
MORITA, CRAIG
|
UNIVERSITY OF IOWA
|
IA
|
$220,974
|
|
Lymphoma
|
NCI
|
5U10CA047642-21
|
|
University of Iowa CALGB Institutional Grant
|
VAENA, DANIEL
|
UNIVERSITY OF IOWA
|
IA
|
$110,413
|
|
Lymphoma
|
NCI
|
2R01CA092153-06
|
|
Molecular Epidemiology of NHL and CLL
|
CERHAN, JAMES
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
MN
|
$629,749
|
|
Lymphoma
|
NCI
|
5K07CA108565-03
|
|
QOL and Service Needs of Leukemia/Lymphoma Survivors
|
PARRY, CARLA
|
UNIVERSITY OF COLORADO DENVER
|
CO
|
$133,703
|
|
Lymphoma
|
NCI
|
5R21CA116127-02
|
|
UCB-DERIVED CD19-SPECIFIC T CELLS FOR UNIVERSAL TREATMENT OF B-CELL MALIGNANCY
|
COOPER, LAURENCE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$168,750
|
|
Lymphoma
|
NCI
|
5R33CA112061-04
|
|
Quantitative proteomic analysis of lymphoma transformation
|
ELENITOBA-JOHNSON, KOJO
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$283,132
|
|
Lymphoma
|
NCI
|
5R01CA124309-03
|
|
Role of PML nuclear body proteins for establishment of EBV latent infection
|
LING, PAUL
|
BAYLOR COLLEGE OF MEDICINE
|
TX
|
$258,530
|
|
Lymphoma
|
NCI
|
5K23CA115682-04
|
|
Genetic Alterations in Families with Multiple Lymphomas
|
BROWN, JENNIFER
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$136,890
|
|
Lymphoma
|
NCI
|
5K23CA109613-04
|
|
Targeting the Mitochondria to Treat Lymphoma and Myeloma
|
EVENS, ANDREW
|
NORTHWESTERN UNIVERSITY
|
IL
|
$131,450
|
|
Lymphoma
|
NCI
|
5R01CA125195-02
|
|
Molecular Pathways in Suppression and Development of T Lineage Lymphomas
|
BASSING, CRAIG
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$312,629
|
|
Lymphoma
|
NCI
|
5R01CA088768-09
|
|
Structure and Molecular Composition of KSHV and RRV
|
KEDES, DEAN
|
UNIVERSITY OF VIRGINIA CHARLOTTESVILLE
|
VA
|
$476,141
|
|
Lymphoma
|
NCI
|
5R21CA129045-02
|
|
Prognostic Genetic Biomarkers for Cancer
|
ONEL, KENAN
|
UNIVERSITY OF CHICAGO
|
IL
|
$122,800
|
|
Lymphoma
|
NCI
|
5R01CA083823-07
|
|
Selective Forces Operative in FeLV Infection
|
LEVY, LAURA
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$268,515
|
|
Lymphoma
|
NCI
|
5R01CA121195-03
|
|
Prediagnostic Markers of Immune Activation and Viral Infection and Risk of NHL
|
MARTINEZ-MAZA, OTONIEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$395,273
|
|
Lymphoma
|
NCI
|
1R01CA134051-01A2
|
|
T Cell Immunity in Endemic Burkitt Lymphoma
|
MOORMANN, ANN
|
CASE WESTERN RESERVE UNIVERSITY
|
OH
|
$485,971
|
|
Lymphoma
|
NCI
|
2R01CA071540-11A2
|
|
Molecular Basis of Action of the Putative Oncogene BCL-6
|
BARDWELL, VIVIAN
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
MN
|
$311,163
|
|
Lymphoma
|
NIAID
|
2R01AI041769-11A1
|
|
Cellular Mechanisms of PTLD in Transplant Recipients
|
MARTINEZ, OLIVIA
|
STANFORD UNIVERSITY
|
CA
|
$354,265
|
|
Lymphoma
|
NCI
|
5R01CA085180-08
|
|
Epstein-Barr Virus LMP-1 Mediated Oncogenicity
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$726,878
|
|
Lymphoma
|
NCI
|
5R01CA113261-05
|
|
Gamma/Delta T Cells Surveillance of B Lymphoma in AIDS
|
PAUZA, C.
|
UNIVERSITY OF MARYLAND BALTIMORE
|
MD
|
$224,720
|
|
Lymphoma
|
NCI
|
1R01CA129132-01A1
|
|
Development of cambinol analogues as antilymphoma agents
|
BEDALOV, ANTONIO
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$365,200
|
|
Lymphoma
|
NCI
|
2P50CA093683-06A2
|
0008
|
Generation of a Therapeutic Antibody Directed Against CCR4 for Patients with
|
MARASCO, WAYNE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$216,958
|
|
Lymphoma
|
NIAID
|
2R01AI076183-06A2
|
|
Structural and Functional Studies of gp42 and HLA Class II in EBV Entry
|
LONGNECKER, RICHARD
|
NORTHWESTERN UNIVERSITY
|
IL
|
$430,471
|
|
Lymphoma
|
NIDCR
|
5R01DE011390-21
|
|
Regulation of Immunity by Prostaglandins
|
PHIPPS, RICHARD
|
UNIVERSITY OF ROCHESTER
|
NY
|
$354,752
|
|
Lymphoma
|
NCI
|
1R01CA128941-01A1
|
|
Regulatory T cells in B cell lymphoma
|
LEVITSKY, HYAM
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$340,300
|
|
Lymphoma
|
NCI
|
2P01CA022443-31
|
0012
|
Plasmid Replicons of Human Tumor Viruses
|
SUGDEN, WILLIAM
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$232,726
|
|
Lymphoma
|
NCI
|
2P01CA022443-31
|
0013
|
Mechanisms of Reactivation of Epstein-Barr Virus from Latency to Lytic Replicatio
|
MERTZ, JANET
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$200,142
|
|
Lymphoma
|
NIBIB
|
2R01EB002991-05A1
|
|
Biofunctional Polymers for Intracellular Drug Delivery
|
STAYTON, PATRICK
|
UNIVERSITY OF WASHINGTON
|
WA
|
$501,959
|
|
Lymphoma
|
NIBIB
|
5R01EB001994-09
|
|
SPECT/CT Image-Based Dosimetry in Radionuclide Tharapy
|
DEWARAJA, YUNI
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
MI
|
$340,393
|
|
Lymphoma
|
NCI
|
5R01CA085721-09
|
|
Experimental Therapy of Cancer by Costimulated Immunity
|
CHEN, LIEPING
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$325,256
|
|
Lymphoma
|
NCI
|
5K08CA114395-03
|
|
Role of Jak3 in Anaplastic Large Cell Lymphoma
|
AMIN, HESHAM
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$136,080
|
|
Lymphoma
|
NCI
|
5R01CA115665-03
|
|
Molecular Mechanisms of Lymphomagenesis
|
MILLS, KEVIN
|
JACKSON LABORATORY
|
ME
|
$289,553
|
|
Lymphoma
|
NIAID
|
5R01AI071928-03
|
|
Regulation of Latent-Lytic Switch in EBV by ZEB
|
MERTZ, JANET
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$350,063
|
|
Lymphoma
|
NCI
|
1K23CA124465-01A2
|
|
Novel Biologic Therapies for Hodgkin's Lymphoma
|
KASAMON, YVETTE
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$140,940
|
|
Lymphoma
|
NCI
|
5K23CA100291-05
|
|
Molecular Classification and therapy of CNS Lymphomas
|
RUBENSTEIN, JAMES
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
CA
|
$127,026
|
|
Lymphoma
|
NCI
|
5K99CA125994-02
|
|
Combining Computational and Experimentation to Interrogate NF-kappaB Signaling
|
COVERT, MARKUS
|
STANFORD UNIVERSITY
|
CA
|
$137,457
|
|
Lymphoma
|
NIAID
|
1K99AI072956-01A1
|
|
Roles for TAK1 in T cell development, function and tumorigenesis
|
WAN, YISONG
|
YALE UNIVERSITY
|
CT
|
$1
|
|
Lymphoma
|
NCI
|
5R01CA057152-14
|
|
Immune Dysfunction and AIDS-associated B Cell Lymphoma
|
MARTINEZ-MAZA, OTONIEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$279,804
|
|
Lymphoma
|
NCI
|
1K08CA127353-01A1
|
|
Epigenetic Mechanisms of Lymphomagenesis.
|
SHAKNOVICH, RITA
|
WEILL MEDICAL COLLEGE OF CORNELL UNIV
|
NY
|
$138,672
|
|
Lymphoma
|
NCI
|
1K24CA128953-01A1
|
|
Development of Immunotherapeutic Strategies in the Treatment of Lung Cancer
|
ANTONIA, SCOTT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$161,259
|
|
Lymphoma
|
NCI
|
5R01CA113454-03
|
|
Targeted Gene Therapy for Lymphoma
|
SMITH, BRUCE
|
AUBURN UNIVERSITY AT AUBURN
|
AL
|
$256,177
|
|
Lymphoma
|
NCI
|
5R01CA109524-03
|
|
IL-7 and Lymphocyte Homeostasis: Life versus Death
|
KHALED, ANNETTE
|
UNIVERSITY OF CENTRAL FLORIDA
|
FL
|
$195,792
|
|
Lymphoma
|
NCI
|
5K08CA101934-06
|
|
Notch-Mediated Apoptosis in Human B Cell Malignancies
|
ZWEIDLER-MCKAY, PATRICK
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$136,080
|
|
Lymphoma
|
NCI
|
5R01CA096500-07
|
|
Role of KSHV K1 in viral pathogenesis
|
DAMANIA, BLOSSOM
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$279,757
|
|
Lymphoma
|
NCI
|
5R01CA087978-09
|
|
HSV Amplicon Activation of Innate and Adaptive Immunity
|
ROSENBLATT, JOSEPH
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$326,561
|
|
Lymphoma
|
NHLBI
|
1R01HL088686-01A2
|
|
Modeling B cell Lymphoma in the Mouse
|
RICKERT, ROBERT
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
CA
|
$477,500
|
|
Lymphoma
|
NCI
|
5K08CA104882-05
|
|
ROLE OF mTOR INHIBITORS AND IL7 IN LYMPHOID MALIGNANCIES
|
BROWN, VALERIE
|
CHILDREN'S HOSPITAL OF PHILADELPHIA
|
PA
|
$138,672
|
|
Lymphoma
|
NCI
|
5R37CA037295-25
|
|
AIDS Associated Lymphoproliferative Disorders
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
NY
|
$432,500
|
|
Lymphoma
|
NCI
|
5R01CA108872-03
|
|
Dysregulation of ubiquitination in MALT lymphomas
|
YANG, XIAOLU
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$244,309
|
|
Lymphoma
|
NCI
|
5R01CA092660-08
|
|
Lymphocyte Survival: Implications for lymphomagenesis
|
THOMPSON, CRAIG
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$310,988
|
|
Lymphoma
|
NIEHS
|
5R01ES015707-02
|
|
Comparative Mechanisms of Genomic Instability
|
VASQUEZ, KAREN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
TX
|
$358,435
|
|
Lymphoma
|
NCI
|
5R21CA128501-02
|
|
High affinity ligand to deliver nanoparticle drugs to lymphoid cancers
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA DAVIS
|
CA
|
$152,000
|
|
Lymphoma
|
NCI
|
5R01CA089194-08
|
|
Jak/STAT signaling in human T-cell lymphomas
|
WASIK, MARIUSZ
|
UNIVERSITY OF PENNSYLVANIA
|
PA
|
$249,891
|
|
Lymphoma
|
NCI
|
1R43CA133979-01
|
|
Profiling methylation of individual CpG sites
|
JIANG, XIN
|
SIGNOSIS, INC.
|
CA
|
$157,290
|
|
Lymphoma
|
NCI
|
5U01CA114778-04
|
|
Molecular Signatures to Improve Diagnosis and Outcome Pr
|
CHAN, WING
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
NE
|
$1,674,031
|
|
Lymphoma
|
NIDCR
|
5R01DE018926-02
|
|
Pathogenesis of oral rhesus lymphocryptovirus infection
|
WANG, FREDERICK
|
BRIGHAM AND WOMEN'S HOSPITAL
|
MA
|
$374,562
|
|
Lymphoma
|
NCI
|
5R01CA121935-03
|
|
Targeted Therapy for Burkitt Lymphoma in Resource Poor Settings
|
HARRINGTON, WILLIAM
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$248,486
|
|
Lymphoma
|
NCI
|
5R01CA122663-03
|
|
A Genome-Wide Association Study of Non-Hodgkin Lymphoma
|
SKIBOLA, CHRISTINE
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
CA
|
$529,626
|
|
Lymphoma
|
NCI
|
5U10CA077440-11
|
|
WUMC-Cancer and Leukemia Group B
|
BARTLETT, NANCY
|
WASHINGTON UNIVERSITY
|
MO
|
$334,932
|
|
Lymphoma
|
NCI
|
5K01CA097283-05
|
|
SATB1-protein Interaction/function at the BcL2 mbr/MAR
|
DURRIN, LINDA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$159,138
|
|
Lymphoma
|
NCI
|
1R43CA134046-01
|
|
Multimodal Diagnostic and Therapeutic Nanoparticles for Non-Hodgkin's Lymphoma
|
CARTIERA, MALGORZATA
|
CARIGENT THERAPEUTICS
|
CT
|
$204,344
|
|
Lymphoma
|
NCRR
|
7R24RR023343-02
|
|
Herpesvirus latency and reactivation in macaque models of human disease
|
ROSE, TIMOTHY
|
CHILDREN'S HOSPITAL AND REG MEDICAL CTR
|
WA
|
$588,518
|
|
Lymphoma
|
NCRR
|
5K01RR023965-02
|
|
Developing New Mouse Models of ATL for Use in Trials of Targeted Therapies
|
ZIMMERMAN, BEVIN
|
OHIO STATE UNIVERSITY
|
OH
|
$126,900
|
|
Lymphoma
|
NCI
|
5K08CA118260-03
|
|
CD20 DNA VACCINATION FOR B-CELL LYMPHOMA
|
PALOMBA, MARIA
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
NY
|
$134,622
|
|
Lymphoma
|
NCI
|
5K99CA129172-02
|
|
The Role of Bcl2L12 in the Genesis of Malignant Glioma
|
STEGH, ALEXANDER
|
DANA-FARBER CANCER INSTITUTE
|
MA
|
$90,000
|
|
Lymphoma
|
NCI
|
5R01CA090571-07
|
|
TCL1 Oncogene in B Lymphocyte Development and Neoplasia
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
CA
|
$266,199
|
|
Lymphoma
|
NCI
|
1F31CA134209-01
|
|
microRNAs Dysregulated by HMG-I in Neoplastic Transformation
|
SMAIL, SHAMAYRA
|
JOHNS HOPKINS UNIVERSITY
|
MD
|
$35,202
|
|
Lymphoma
|
NCI
|
4R37CA057138-18
|
|
MYC ONCOPROTEIN FUNCTION
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
WA
|
$821,506
|
|
Lymphoma
|
NCI
|
2P01CA022443-31
|
0010
|
Inhibiting The Survival And Proliferation Of EBV-Associated Tumor Cells
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$233,184
|
|
Lymphoma
|
NCI
|
1P50CA128346-01A1
|
0004
|
Developmental Projects
|
MATTREY, ROBERT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$120,000
|
|
Lymphoma
|
NCI
|
5K01CA122192-02
|
|
Cooperation of PTEN and SHIP as tumor suppressors in B-Cells
|
PEDERSEN, IRENE
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
CA
|
$108,558
|
|
Lymphoma
|
NCI
|
1R01CA130752-01A1
|
|
Analysis of Epstein Barr virus type III latency on cellular miRNA gene expression
|
FLEMINGTON, ERIK
|
TULANE UNIVERSITY OF LOUISIANA
|
LA
|
$309,175
|
|
Lymphoma
|
NHLBI
|
5R01HL083050-04
|
|
Abnormalities in gene expression in therapy-related MDS
|
BHATIA, RAVI
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
CA
|
$552,720
|
|
Lymphoma
|
NCI
|
2R01CA073507-11A2
|
|
In Vivo Model of Epstein-Barr Virus Latency
|
LONGNECKER, RICHARD
|
NORTHWESTERN UNIVERSITY
|
IL
|
$377,500
|
|
Lymphoma
|
NCI
|
5R01CA112217-03
|
|
Targeting of EBV Latency in Burkitt's Lymphoma
|
HARRINGTON, WILLIAM
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
FL
|
$236,524
|
|
Lymphoma
|
NHLBI
|
5R01HL064851-08
|
|
New EBV Therapies for treating malignancies
|
PAGANO, JOSEPH
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
NC
|
$346,086
|
|
Lymphoma
|
NCI
|
5R21CA125398-02
|
|
The Kinomes of Non-Hodgkin Lymphoma
|
KERR, WILLIAM
|
H. LEE MOFFITT CANCER CTR & RES INST
|
FL
|
$162,270
|
|
Lymphoma
|
NCI
|
2R01CA066519-14A1
|
|
EBV-based Strategies for AIDS-related Malignancies
|
KENNEY, SHANNON
|
UNIVERSITY OF WISCONSIN MADISON
|
WI
|
$276,467
|
|
Lymphoma
|
NCI
|
1R01CA132638-01A1
|
|
Anti-viral IL6 approach to mitigate KSHV-related disease
|
WONG, SCOTT
|
OREGON HEALTH AND SCIENCE UNIVERSITY
|
OR
|
$643,832
|
|
